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Abstract 
The theory stating that oxidative stress (OS) is at the root of several diseases is 
extremely popular. However, so far, no antioxidant is recommended or offered by 
healthcare systems neither approved as therapy by regulatory agencies that base their 
decisions on evidence-based medicine (EBM). This is simply because, so far, despite 
many preclinical and clinical studies indicating a beneficial effect of antioxidants in 
many disease conditions, randomised clinical trials have failed to provide the 
evidence of efficacy required for drug approval. 
In this review, we discuss the levels of evidence required to claim causality in 
preclinical research on OS, the weakness of the oversimplification associated with OS 
theory of disease and the importance of the narrative in its popularity. Finally, from a 
more translational perspective, we discuss the reasons why antioxidants acting by 
scavenging reactive oxygen species (ROS) might not only prevent their detrimental 
effects but also interfere with essential signalling roles. We propose that ROS have a 
complex metabolism and are generated by different enzymes at diverse sites and with 
different timing. Aggregating this plurality of systems in a single theory of disease 
may not be the best way to develop new drugs, and future research may need to focus 
on specific oxygen-toxifying pathways rather than on non-specific ROS scavengers. 
Finally, similarly to what is nowadays required for clinical trials, we recommend 
making unpublished data available in repositories (open data), as this will allow big 
data approaches or meta-analyses without the blinders of the publication bias. 
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The oxidative stress theory and its translational gap 
 
Background 
The theory that oxidative stress (OS) is at the basis of many diseases is widely 
popular, but so far antioxidants have not been approved for any indication because 
they did not meet the criteria of efficacy for drug approval. To address this problem 
from a novel perspective, we will analyse the reasons for the popularity of the OS 
theory of disease and its scientific basis. In doing so, we need to consider various 
aspects participating in the development of scientific theories in biology and 
medicine. First, we will summarise the type of evidence required to approve a drug. 
Then we will discuss if it is possible to grade the level of evidence in preclinical 
research to assess the strength of a scientific hypothesis. We will also discuss the 
concept of causality and the role of mechanisms in scientific hypotheses and their 
acceptance. Finally, we will discuss the importance of mechanisms in the 
development of new therapies and analyse the OS theory of disease in the light of 
some concepts developed in epistemological research.  
 
The classical oxidative stress theory of disease 
The concept behind the OS theory of disease is that the metabolism of molecular 
oxygen (O2) by the cell results in the production of reactive oxygen species (ROS), 
including hydrogen peroxide (H2O2), hydroxyl radical (OH.) and superoxide radical 
(O2.), which can be toxic by reacting with cellular macromolecules. For this reason, 
organisms have developed antioxidant defence systems to eliminate ROS. These 
include enzymes, such as superoxide dismutase (SOD) and peroxidases, and small-
molecular weight antioxidants (vitamin E, vitamin C, glutathione (GSH)). Despite the 
fact that the concept of OS has evolved in recent years (Jones! &! Sies,! 2015), this 
concept is popularised as a balance with ROS on one plate and antioxidants on the 
other (Figure 1). OS occurs when ROS production exceeds the antioxidant systems 
(either because of an increased ROS generation or a decrease in antioxidants). 
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Figure 1. The classical schematic representation of the OS theory 
 
In 1956, Harman, postulated the “free radical theory of ageing” hypothesizing that the 
degenerative process of ageing has a free radical mechanism in common with cancer 
and radiation toxicity (Harman, 1956). Harman immediately caught the possible 
implications in that “This theory is suggestive of chemical means of prolonging 
effective life” (Harman, 1956). The early 1970s also saw the publication of Linus 
Pauling’s book “vitamin C and the common cold” [(Pauling, 1970) p.36].  However, 
the term OS did! not! appear! in! the! scientific! literature! until! 1970, in a study on 
erythrocyte damage induced by H2O2 (Paniker, Srivastava & Beutler, 1970). Since 
then, many papers were published suggesting, often with very convincing data, that 
OS is associated with many diseases, and that antioxidants would have a beneficial 
effect. Today it is a challenge to find a disease for which a role of OS has not been 
postulated. Searching the phrase “caused by oxidative stress” in Google in October 
2015 gave 220,000 hits.  Most websites and review articles on this subject will have a 
scheme similar to that in Figure 2. The main purpose of this paper is to discuss the 
exact meaning of those arrows and their directions. 
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Figure 2. A typical scheme generalizing the OS theory of disease 
 
The lack of translational success of the classical OS concept 
The appeal of the OS theory of disease resides in its translational implication that 
antioxidants, by scavenging ROS, could be beneficial in all the diseases in Figure 2, 
and additionally would ensure healthy aging; too good to be true? So far, no 
antioxidants have been approved for any indication by regulatory agencies such as the 
Food and Drug Administration (FDA), or the European Medicines Agency. Despite 
their low cost, no antioxidant supplements are reimbursed/offered by public health 
insurance systems of most countries.  Only in Japan, a free radical scavenger, 
edaravone, is approved for stroke and amyotrophic lateral sclerosis (Abe et al., 2014; 
Wada et al., 2014). Probably the most famous failure was the free radical-trapping 
agent NXY-059 that, despite strong preclinical data in stroke, failed to show efficacy 
in a large clinical trial, casting doubt on the significance of basic research in this field 
(Feuerstein et al., 2008). Several studies have shown that, in many diseases, 
antioxidant supplements are ineffective or even harmful (see a meta-analysis of 78 
studies in (Bjelakovic, Nikolova, Gluud, Simonetti & Gluud, 2012)).  While this 
could be due to problems of the drugs tested or the trial design, there may also be 
weaknesses in the OS theory of disease due, for instance, to the fact that ROS have 
beneficial physiological roles (“redox regulation”, discussed in 3.1). 
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Despite this lack of evidence, the OS theory of disease is so popular that antioxidants, 
including vitamins C and E, GSH, some metals (e.g. selenium and zinc) or extracts 
from a wide range of fruits, vegetables or fish, are the lion’s share of the nutritional 
supplements used by 150 million Americans (Starr, 2015). These supplements are 
used as they supposedly strengthen immune defences, prevent cancer or pathological 
ageing. “Antioxidants are good and free radicals are bad” became one of the “science 
myths that will not die” (Scudellari, 2015). 
 
Level of evidence required in translational medicine 
Antioxidants, like any other drug, need evidence to be approved as treatment for any 
indication. For a new drug to be approved for a specific indication, one must provide 
strong evidence of efficacy on a large population and on disease-relevant endpoints 
(Downing, Aminawung, Shah, Krumholz & Ross, 2014; Katz, 2004). These criteria 
are based on a hierarchy of evidence, with expert opinion and small case-control 
studies at the bottom, and randomised clinical trials (RCT) and meta-analyses of RCT 
at the top (Medicine, 2009) (Evidence-Based Medicine Working Group, 1992; 
Howick, 2011; Jeremy et al., 2011). On the other hand, the US FDA criteria for 
making a health claim regarding a nutritional supplement are less stringent. Two types 
of health claims are allowed: “health claims” and “qualified health claims” (Ellwood, 
Trumbo & Kavanaugh, 2010). Health claims require “significant scientific 
agreement” on the relationship between the supplement and a disease, meaning that 
“the validity of the relationship is not likely to be reversed by new and evolving 
science, although the exact nature of the relationship may need to be refined” 
(Ellwood, Trumbo & Kavanaugh, 2010). On the other hand, a “qualified health 
claim” when “the evidence for a substance/disease relationship is credible but does 
not meet the significant scientific agreement standard” (Ellwood, Trumbo & 
Kavanaugh, 2010), and in this case the claim should be mitigated with a disclaimer.   
 
Levels of evidence in basic research 
Experimental strategies 
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Basic research lacks commonly accepted criteria to assess the level of experimental 
evidence required to conclude, for instance, that “OS is implicated in disease x” or 
“antioxidants could be useful in disease y”.  The strength of the evidence may, or may 
not, be questioned during the peer review process, but it is unlikely that the reviewers 
will question the OS theory of disease. If we analyse the morphology of the literature 
on the OS theory of disease we can come up with a few basic types of experimental 
evidence, described in Table 1. !!
Table  1. Main  experimental approaches in the study of the OS theory of disease 
 
Studies based on testing the effect of ROS or antioxidants on a disease-related 
process 
1. Studies investigating the effect of ROS on disease-related pathway (e.g.: H2O2 
induces aggregation of alpha-synuclein, a protein important in Alzheimer’s disease 
(Hashimoto et al., 1999); adding H2O2 to immune cells causes the production of 
inflammatory mediators (DeForge, Preston, Takeuchi, Kenney, Boxer & Remick, 
1993); injecting a H2O2-generating enzyme in the mouse knee joint causes 
inflammation (Schalkwijk, van den Berg, van de Putte & Joosten, 1986)). 
2. Studies investigating the effect of an antioxidant on a disease-related pathway (e.g.: 
polyphenols present in red wine inhibit formation of amyloid fibrils, that are 
important in Alzheimer’s disease (Ono, Yoshiike, Takashima, Hasegawa, Naiki & 
Yamada, 2003); antioxidants inhibit TNF production in vitro and in vivo in mice 
(Chaudhri & Clark, 1989); antioxidants from red wine are protective in animal models 
of stroke (Yu et al., 2016); clinical trials with antioxidants). 
3. Study of the effect of genetic modification (knock out, overexpression) or 
modulation of antioxidant enzymes or ROS-generating enzymes, on a disease-related 
pathway or an animal model of disease (Sorce et al., 2014). 
 
Studies based on measuring ROS or antioxidants in a disease or its model 
1. Studies showing that ROS are produced in a disease or a disease model (e.g. ROS 
are generated during the aggregation of amyloid peptides implicated in Alzheimer’s 
disease (Tabner et al., 2005); ischemia causes activation of a ROS-producing enzyme, 
xanthine oxidase (Granger, 1988); an indicator of ROS production, malondialdehyde, 
is elevated in blood from patients with systemic lupus erythematosus (Wang, 
Pierangeli, Papalardo, Ansari & Khan, 2010)). 
1. Studies showing that endogenous antioxidants are decreased in a disease or disease 
models in vitro or in vivo, or in patients (e.g. levels of plasma antioxidants are lower 
in osteoporotic patients (Maggio et al., 2003)). 
3. Genome-wide association studies where a mutation in a gene for a ROS-generating 
enzyme or an antioxidant protein is associated with a disease. !
Different experimental systems can be used: 1) cell-free; 2) in vitro (cell culture); 3) 
in vivo (animal models or patients).  These experimental interventions, however, often 
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suffer from lack of specificity; while testing the effect of ROS, one can for instance 
add H2O2 or a ROS-generating system to cell culture, but adding an antioxidant is not 
the same as “removing ROS”. This may be true when adding SOD or catalase, as they 
specifically remove superoxide and H2O2 respectively, but it is certainly not the case 
with small-molecular weight antioxidants, which usually have other chemical 
properties and biological activities than removing ROS (Forman,! Ursini! &! Maiorino,!2014;! Ohlow! &! Moosmann,! 2011). For instance, exogenously-administered 
antioxidants can down-regulate endogenous antioxidant enzymes (Gomez-Cabrera et 
al., 2008; Ristow et al., 2009) 
The difficulty is to rank the level of evidence obtained in different experimental 
models. Common sense suggests that in vivo models rank higher than in vitro 
systems, or that extrapolations from in vitro experiments with primary cells are more 
trustworthy than those obtained with immortalised cell lines (Baetu, 2015). While this 
may be true in some cases, this may not apply to studies on OS. Indeed, it is difficult 
to appreciate whether the decreased production of an inflammatory mediator observed 
in vitro following addition of an antioxidant to purified blood cells from rheumatoid 
arthritis (RA) patients represents a higher level of evidence than the effect of the 
administration of the same antioxidant on joint swelling in a chronic mouse model of 
RA in vivo.  
In the next sections, we try to apply the knowledge from current epistemological 
studies to the problem of the OS theory of disease, to identify potential weaknesses 
and priorities for future research.  
 
Causality and the problem of confounding 
In biomedical research, we often search for the specific association between two 
parameters or events. If we found a statistically significant association between OS 
and RA (for instance, the levels of oxidised proteins in blood are higher in RA), we 
could hypothesise a causal link between the two variables, that is: i) OS causes RA, or 
ii) RA causes OS. The direction of the arrow is influenced by common wisdom, 
dominant or popular theories in the field, or other factors; most will probably favour 
the first hypothesis, with the arrow pointing from OS to RA.  
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However, the simple association of ROS production and a disease does not mean that 
ROS cause the disease: an association does not always mean causation. The possible 
interpretation of an association between two variables is described in Figure 3 (a-b) 
(for instance see (Illari, Russo & Williamson, 2011), p.79).  The first example (a) is 
an association with a simple causal link (C causes E). The “sign” of the causal link 
may be positive or negative (for instance, respectively, “autoimmunity causes 
diabetes” or “low insulin causes diabetes”).  The second example (b) is a situation 
where the association between C and E is not due to a causal link but to a third 
variable F that acts as a confounder.  A typical example is the possible causal link 
between yellow fingers and lung cancer; both are caused by cigarette smoking, the 
confounder, and, when this is taken into account, the causal link between C and E 
disappears (Smith & Phillips, 1992).  
 
Figure 3. Schematic representations of causal mechanisms 
 
We can try to apply the scheme of a causal mechanism to the example of RA. 
Measurements of indicators (biomarkers) of OS and animal experiments suggest a 
link with OS (Hitchon & El-Gabalawy, 2004), with papers stating that 
“rheumatologists . . . may also consider incorporating antioxidant therapeutics in their 
prescriptions” (Taysi, Polat, Gul, Sari & Bakan, 2002). If we analyze the causal 
mechanism described above should we conclude that, because markers of OS are 
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elevated, “OS causes RA” (Figure 3c)? If we consider the scheme (b), could there be 
a third variable that causes both OS and RA? For example, RA is an autoimmune 
disease where activated CD4+ T lymphocytes produce mediators such as interleukin  
(IL-) 17 that, in turn, activate inflammation in the joint which causes the symptoms of 
RA (swelling, pain, tissue damage) (Firestein, 2003; van den Berg & Miossec, 2009). 
Because inflammation can cause production of ROS by inflammatory cells (Smith, 
1994), inflammation could well be the confounder, and thus the common cause of 
both RA and OS. In this case, the two variables, RA and OS, are not causally linked.  
That would make a big difference in translational medicine because only if there was 
a causal link, “OS causes RA”, one could hypothesise that eliminating ROS with 
antioxidants might improve the disease. 
The first two schemes provided in Figure 3, mainly derived from epidemiological 
research, are sketchy, and causal mechanisms can be more complicated. By adapting 
schemes developed for experimental studies of mediation in the social sciences to the 
OS/RA case, (Imai, Keele, Tingley & Yamamoto, 2011), we could have different 
mechanisms interacting with each other (Figure 3 d-f). Autoimmunity could induce 
RA directly, for instance with autoreactive T cells attacking the joints, or indirectly 
via ROS as mediators (d). Scheme (e) shows a more complex mechanism where two 
measured mediators are involved, ROS and (for example) the T cell-derived cytokine 
IL-17 (van den Berg & Miossec, 2009). In this scheme the two mediators are 
independent but there are other possibilities, where the two mediators are not 
independent (f). There are many more possibilities with other mediators and 
moderators (Edwards & Lambert, 2007; Imai, Keele, Tingley & Yamamoto, 2011), 
often with unobserved or unknown mediators involved, and more complex causal 
schemes can be drawn (Hernan, Hernandez-Diaz, Werler & Mitchell, 2002; Robins, 
2001).  
 
Causality and the sufficient-component cause model 
The other problem is that most diseases are multifactorial. A conceptual model, 
known as the “sufficient-component cause model”, originally described by Rothman 
in 1976 (Rothman, 1976), states that a disease may be caused by several factors 
(component causes) that act together to cause the disease. Importantly, a disease may 
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have more than one sufficient cause, each of them made of several component causes. 
An example describing various component causes of tuberculosis is given in Figure 4.  
 
Figure 4. Rothman’s sufficient component model of tuberculosis causation. 
Modified from Prof. Wayne LaMorte, Boston University  School of Public Health 
(personal communication). 
 
In this example, three different situations (sufficient causes) can cause tuberculosis. 
Each of these sufficient causes is made of more than one “component cause”, not 
necessarily the same ones.  In this case, however, one component cause is necessary - 
exposure to Mycobacterium tuberculosis (M.Tb). 
Taking the Rothman model into consideration, we should not just ask if a disease is 
caused by OS, but whether there are diseases where OS is a component cause, and 
whether OS in necessary or not.  The Rothman’s model has important implications in 
translational medicine because a biochemical process (like OS) may not have the 
same role in all patients with the same disease. In a recent review on biomarkers of 
OS, we discussed their potential usefulness in patient stratification in clinical trials to 
identify those who could benefit from therapies that target OS (Frijhoff et al., 2015). 
 
External validity: extrapolation and reductionism 
The problem of external validity is how an observation or a theory is generalizable 
(Johnson, 1997), and if it can be translated to the clinic.  This is inextricably linked to 
the experimental models used.  In the laboratory, we use extremely simplified models 
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and experiments are performed in a controlled environment to avoid exactly those 
confounders (other biochemical pathways and component causes, factors for which 
we often have only a partial knowledge) that are present in real life.  
 This is what philosophers call reductionism. Upon extrapolation from in vitro or 
animal models to a clinical setting, reductionism hits back with what Steel called the 
“extrapolator’s circle”, i.e. the challenge “to explain how the suitability of the model 
as a basis for extrapolation can be established given only limited information about 
the target” (Steel, 2007) [p.4]. The reductionist approach makes it difficult to design 
experiments aimed at falsifying the hypothesis, considered by Popper as the key of 
the scientific method (Popper, 2005). As noted by Bechtel, “Confirmation is 
challenging because there are always alternative possible laws from which one might 
make the same prediction . . . Falsification is challenging because a false prediction 
might be due to an error either in the proposed law or in one of the auxiliary 
hypotheses that figured in deriving the prediction.” [(Bechtel, 2006) Page 61]. 
For instance, if we want to test the hypothesis that hydrogen peroxide causes bone 
damage in RA, we may administer a thiol antioxidant to an animal model where the 
disease is induced by promoting an autoimmune response to collagen. If the 
antioxidant didn’t work, that doesn’t negate the hypothesis as the antioxidant might 
not reach the site of inflammation at the right concentration, have non-specific effects 
or decrease ROS at other sites and should not be considered a clear-cut tool.  
 
Reductionism in the representation of scientific theories 
Reductionism plays an important role in the way we represent mechanistic theories 
and causal links.  Scientists “rarely depict all the particular details when describing a 
mechanism; representations are usually schematic, often depicted in diagrams.”  
(Darden, 2005). Mayer pointed out the downside of the overuse of diagrams in 
modern science: “ . . . the typical ‘cartoon’ of signalling pathways, with their 
reassuring arrows and limited number of states could be the real villain. Instead of 
simplifying an inherently complex system so that the key points can be grasped, we 
would argue that such diagrams actively mislead, implying a specificity and 
homogeneity that does not at all reflect the messy reality of actual signalling 
complexes.” (Mayer, Blinov & Loew, 2009).  In fact, if we think of the 
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representations of the Krebs cycle or the glycolytic pathway, they look like complete 
representations of the metabolic pathway. However, if we were to draw a metabolic 
table describing all the protein thiol disulfide oxidoreductases (thioredoxin, 
glutaredoxin, peroxiredoxins, sulfiredoxin etc.) it would be very difficult to give a 
comprehensive description in one figure to include, for instance, the over 100 protein 
substrates of thioredoxin and the various sources of the different ROS.  When we try 
to zoom out from a specific biochemical pathway to describe our hypothesis about a 
role of OS in disease, the focus of the diagram is completely lost. It often results in 
diagrams, such as that in Figure 5, where we mix different levels: molecules (H2O2, 
NH4), subcellular organelles, cells, organs and diseases; the resulting diagram will 
clearly have many implicit black boxes. Of note, there is nothing wrong in these 
graphs, as long as we are aware of the limitations due to our incomplete knowledge of 
the system. 
 
  
Figure 5. Diagram of a pathogenic mechanism involving ROS. Reproduced with 
permission from: (Casas et al., 2015). 
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Reductionism in the use of proxy biomarkers 
For the germ theory of disease, demonstration needs to fit the so-called Koch’s 
postulates: 1) detection of the germ in every patient; 2) the germ is not present in 
other diseases; 3) the isolated germ can induce the disease if re-injected.  Are there 
any such criteria we could use for the OS theory of disease? Of course the first two 
postulates cannot be met in the case of a component cause, and because OS could 
mediate other diseases. However, the real problem is measuring ROS in disease. ROS 
are unstable and their half-lives range from 10-9 s for the hydroxyl radical (OH.) to 10-
3 s for H2O2 (D'Autreaux & Toledano, 2007), making them nearly impossible to 
measure in patients. Therefore, ROS are measured using biomarkers as proxies, which 
are often insufficiently validated. These are, in most cases, reaction products resulting 
from the reaction of ROS with cellular molecules (see (Frijhoff et al., 2015) for a 
recent review), and are seldom specific, as they can be a result of interaction of 
cellular molecules with more than one ROS, or can be generated by other metabolic 
pathways. For instance, the most used OS biomarker, malondialdehyde (MDA) 
(Janero, 1990), (40,000 publications) has been measured by several techniques, often 
non-specific and hard to compare. MDA is one of the terminal products of the 
peroxidation of several polyunsaturated fatty acids.  Although this reaction can be 
initiated by ROS, it has many biases:  we do not know exactly from which lipid it is 
derived, which ROS contributes to its production, and from which tissue it originates, 
unless it is measured properly by chromatographic methods (Frijhoff et al., 2015); 
furthermore, MDA has been widely used as a measure of a different pathway, 
prostaglandin synthesis (Smith, Ingerman & Silver, 1976). 
Biomarkers of OS are probably not the best proxies when compared with other 
biomarkers (haematocrit for anaemia; glucose or insulin levels for diabetes; C-
reactive protein for inflammation; fever for infection). These biomarkers only provide 
very indirect evidence of OS, and even more indirect evidence of ROS production. As 
of today, no biomarker of OS provides information on the cellular source, tissue or 
organ involved (when measured in circulation).  The technical difficulties of 
measuring ROS, together with the lack of specificity of the most used biomarkers of 
OS, are probably the weakest link in the OS theory of disease. 
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Causality and mechanism. Disease mechanisms versus mechanisms of actions of 
drugs 
Illari and Williamson stated: “A mechanism for a phenomenon consists of entities and 
activities organised in such a way that they are responsible for the phenomenon.” 
(Illari & Williamson, 2012). Mechanisms include several entities and their causal 
interactions (Hernandez-Lemus & Siqueiros-Garcia, 2015).  We are interested in 
identifying the pathogenesis of diseases, not least because the elucidation of 
mechanisms can lead to the development of new drugs. For instance, the 
identification of the cascade of inflammatory cytokines as the (complex) mechanism 
by which autoimmunity causes inflammation (Feldmann, Brennan & Maini, 1996) led 
to development of the inhibitors of IL-6, IL-17 and TNF currently used in the therapy 
of RA.  
However, do we really need a mechanism to develop new drugs? Russo and 
Williamson maintain that, historically, knowledge of a mechanism is important in 
accepting a causal claim (Russo & Williamson, 2007). They give the example of 
Semmelweis’ finding that puerperal fever and deaths were associated with cadaveric 
contamination, and could be prevented by washing hands with chlorine; this was only 
accepted by the scientific community 20 years later, when the development of the 
germ theory of disease by Pasteur provided a mechanism to this finding (Russo & 
Williamson, 2007).   On the other hand, Howick lists some treatments, vaccines in the 
first place, that were widely accepted before any hint of a mechanism was known 
(Howick, 2011) [p.131-132]. A more recent example is the screening program of the 
US National Cancer Institute (NCI) in the 1980s, involving empirical screening of 
chemicals and natural products for their cytotoxicity against a panel of tumour cell 
lines. This led to the identification of several drugs now used in oncology, before the 
NCI adopted mechanism-based screening strategies (Balis, 2002; Cragg, 1998).  
Common sense suggests that a drug developed based on a known mechanism of 
action and a hypothesis for the pathogenesis of a disease should have better 
probability of showing efficacy in a RCT than a drug tested at random, a view 
probably shared by many scientists. The importance of the mechanism of action in 
predicting the efficacy of a drug is a matter of debate, but not from the regulatory 
point of view. As Katz summarised, the FDA has an empirical approach. Information 
about the mechanism of action is important but “entirely subsidiary to the 
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fundamental questions that must be answered in the course of drug approval; namely, 
is a drug effective, and is it safe in use.” (Katz, 2004). These questions, Katz writes, 
cannot be answered by the understanding of the mechanism of action, mainly because 
this understanding will always be incomplete. The FDA limits the usefulness of 
animal and in vitro studies to the generation of hypotheses or exploration of 
mechanisms but states that “these studies do not provide information from which 
scientific conclusions can be drawn regarding a relationship between the substance 
and disease in humans” 
(http://www.fda.gov/food/guidanceregulation/guidancedocumentsregulatoryinformati
on/ucm073332.htm). 
The empiricist position adopted by the FDA does not mean that we should not 
develop drugs targeting specific mechanisms. It only means that this should not give a 
drug an advantage over another for which the mechanism is unknown.  It is fair to 
note that some think that an unsuccessful trial does not necessarily falsify the 
hypothesis on disease mechanisms or on the mechanisms of action of a drug, and 
might be due to off-targets activities (Mann & Mochly-Rosen, 2013). 
We need to clarify the relationship between the “mechanism of action of a drug” and 
“pathogenic mechanism of a disease”. In many cases, the mechanism of action of a 
drug is very well characterised; for instance, receptor antagonists or antibodies to an 
inflammatory cytokine or a cancer antigen. If there are already drugs on the market 
that have a specific mechanism of action, new drugs with the same mechanism of 
action on a “validated target” have a better approval rate than the industry average 
(Falconi, Lopes & Parker, 2014; Kola & Landis, 2004). The fact that there are no 
antioxidants approved means that ROS are not (yet) “validated targets”. Furthermore, 
we have only limited knowledge of the diseases for which OS is a clear cause, at least 
if we adopt stringent criteria.  
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Howick stated that one of the reasons why knowledge of the mechanism of action of a 
drug does not automatically predict its effectiveness is because this knowledge is 
incomplete, making the example of the mechanism of action of antiarrhythmic drugs, 
describing this graphically as a black box (Figure 6). The mechanistic reasoning (left) 
predicted that these drugs would have improved survival in patients but actually 
increased mortality (Howick, Glasziou & Aronson, 2013). 
 
Figure 6. Black boxes in the mechanism of drug action: the example of 
antiarrhythmic drugs.  Modified from (Howick, Glasziou & Aronson, 2013).  
 
How much we know of the mechanisms underlying OS, the role of OS in a specific 
disease, and the mechanism of action of antioxidants and their specificity is important 
in determining how black is the black box.  The fact that the list of diseases found in 
reviews on OS is so long to include practically all of them is not particularly helpful. 
It is therefore a priority to identify a hierarchy of levels of evidence for the OS theory 
of disease, but this will be extremely difficult. When taking the theory of OS from the 
bench to the bedside using antioxidants as drugs we are adding the problem that most 
of them, more than most drugs, will have off-target effects, or that ROS may have 
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physiological functions beyond their toxic effects. The following section describes 
other aspects that may help explain the popularity of the OS theory of disease and of 
the use of antioxidants despite EBM-level evidence. 
 
The importance of narrative: teleological perspectives 
St. Thomas Aquinas thought that natural objects and organisms have a function, and 
understanding the natural world is to see how objects fit into a teleological hierarchy 
((Perlman, 2009) p. 152). Teleology (from the Greek thelos, end, goal) or goal-
directedness is deeply rooted in the descriptive language of biology (Toepfer, 2012).  
Salmon, in the Introduction to the Philosophy of Science (Salmon, 1999).p.14] asks 
whether explanation involves reduction to the familiar and notes that the type of 
explanation we are best acquainted with is an anthropomorphic one (Mayr, 1998), in 
which actions are explained in terms of conscious purposes (Salmon, 1999). p.14]. In 
fact, we often use expressions like “the purpose of polymorphonuclear neutrophils is 
to kill bacteria” or describe the heart as a machine whose purpose is to pump blood. 
However, the term “teleological” is not precise, and scholars distinguish between 
“real” teleological systems (end-seeking), teleonomic systems (end-resulting, with a 
purpose due to the operation of a program) and teleomatic systems (end-resulting but 
not goal seeking, and having no purpose) (Mayr, 1974; Mayr, 1998). The example of 
a teleomatic process is any process governed by a natural law: the decay of an isotope 
or the evaporation of water; there is an end but this is not the result of a program or 
the accomplishment of a purpose.  
One pillar of the OS theory of disease is that there are a number of antioxidant 
systems whose function is to protect the organism from ROS generated by cellular 
metabolism.  If we agree that SOD and catalase evolved to eliminate superoxide 
(reaction I) and hydrogen peroxide (reaction II), we could probably refer to them as 
teleonomic systems – with the purpose of catalysing specific reactions. 
2 O2●-  +  2H+   ! H2O2 + O2  (SOD) (I) 
2 H2O2 ! 2 H2O + O2  (catalase)  (II) 
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Let us now consider other processes associated with OS, such as protein 
glutathionylation, a process by which a free cysteine in a protein (Prot-SH) and the 
cysteine of GSH react to form a mixed disulfide (termed glutathionylated protein, 
Prot-SSG).  We often read that protein glutathionylation has a purpose, for example to 
protect protein thiols from irreversible oxidation, or as a regulatory mechanism 
(Dalle-Donne, Rossi, Giustarini, Colombo & Milzani, 2007; Mieyal & Chock, 2012); 
is this what we actually mean?  Because GSH is in equilibrium with its oxidised form 
(its disulfide, GSSG), it will inevitably undergo thiol-disulfide exchange with Prot-SH 
(reaction III), provided some conditions of accessibility and pK of the Prot-SH are 
met. In the same way, Prot-SH will inevitably react, to an extent determined by the 
equilibrium, with GSH (reaction IV). 
Prot-SH + GSSG ! Prot-SSG +GSH  (III) 
Prot-SH + GSH ! Prot-SSG    (IV) 
If we have Prot-SH, GSH and GSSG, as we have them in every cell, the above 
processes are inevitable, and we should regard them as teleomatic – without a 
purpose.  These reactions may have results and consequences, but not a purpose.  
Attributing a purpose to teleomatic reactions oversimplifies complex networks and, 
by tagging a chemical reaction as “good” or “bad” may create false pharmacological 
targets. The same line of reasoning could apply to irreversible forms of cysteine 
oxidation. For instance oxidation of specific cysteine in a peroxiredoxin can switch its 
activity from a peroxidase to a chaperone (Lim et al., 2008); thus even irreversible 
oxidation should not necessarily be interpreted as a form of protein damage. 
The importance of the narrative is the success of a theory and a medical practice: 
ROS as the axis of evil and antioxidants as the Holy Grail 
If we consider the association mentioned above (OS and RA) and ask a medical 
scientist to draw a causal link for the association between ROS production and RA, it 
is likely that he or she would draw an arrow from ROS/OS to RA and not vice versa 
(although that could very well be the case!). This makes a “better story” and fits well 
in the existing theories. Stories are not just for the layperson; the idea that successful 
papers should “tell a good story” is hardcoded into researcher’s minds (Shermer, 
2007). Even when assessing the validity of a scientific model, some will say “a model 
is valid to the extent that the story being told using that model holds” (Illari, 2012). 
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However, not always are a good mechanism and a good story predictive of the 
efficacy of a treatment; bloodletting, used until a century ago, was popular because it 
fits with the Greek theory of the four humors (Howick, 2011) (p.136-137). 
The OS theory of disease is based on an even more attractive narrative, the fight 
between good and evil, antioxidants preventing ageing like the Holy Grail or acting 
like shields against ROS, an imagery and wording often used even by scientists in 
their review articles or presentations. As added value, main sources of antioxidants 
are fruit and vegetables (Moon & Shibamoto, 2009; Ramos, 2008); ROS are the 
germs and antioxidants the antibiotics.  This has probably a key role in the popularity 
of the OS theory of disease and of its translational shortcut, the use of antioxidant 
supplements. 
 
Un-shading the black box; adding complexity 
From the concept of OS to that of redox regulation 
Oxidation of protein cysteines has been regarded as one of the many forms of 
oxidative damage (Stadtman, 1992). The concept of redox regulation (Ray, Huang & 
Tsuji, 2012) is based on the fact that the activity of several proteins is regulated by 
reversible oxidation of protein cysteines (Fig 7). This scheme is very similar to the 
prototypic mechanism of regulation of protein activity by phosphorylation, where a 
phosphate group from ATP is reversibly attached to a protein.  Examples of redox-
regulated proteins are the transcription factor NF-kB, which is activated by ROS and 
inhibited by thiol antioxidants (Schreck, Rieber & Baeuerle, 1991), and the 
transcriptional regulators Keap1-Nrf2 (Wakabayashi et al., 2004). In the scheme in 
Figure 7, thiol antioxidants act not only by scavenging ROS (both physiologically 
produced or pathologically over-produced) but can also directly reduce protein 
disulfides, independently of an effect on ROS. 
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Figure 7. Regulation of protein function by reversible oxidation (top) and by 
phosphorylation (bottom). 
 
Recent evidence shows that ROS have signalling activity in vivo and that their 
elimination may have negative effects as it removes one component of the pathway 
(Ristow et al., 2009). Furthermore, decreasing ROS may increase the levels of other 
reactive species, such as nitric oxide (Gryglewski, Palmer & Moncada, 1986). 
One way we attempt to reconcile the two actions of ROS (physiological in redox 
regulation and pathological in the OS theory of disease) is by assuming that low 
amounts of ROS are necessary due to their participation in signalling, but excessive 
production is damaging. This has an impact on the therapeutic strategies using 
antioxidants acting as ROS scavengers to “mop up” ROS. It would be extremely 
difficult to titrate the dose of antioxidant to inhibit only the excess ROS present in 
some diseases without decreasing the “physiological” levels.  
 
Getting the whole picture; adding complexity rather than reducing 
From the pharmacological point of view one way forward is to look for specific ROS 
sources as drug targets instead of scavenging ROS in general, as discussed elsewhere 
(Casas et al., 2015). If an enzyme Z is responsible for overproduction of ROS in a 
specific tissue and disease, it may be more effective to inhibit its activity rather than 
“mopping up” all ROS anywhere and by any source. To come back to the analogy of 
protein phosphorylation, a successful way to target an oncogene has been to inhibit a 
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specific kinase with imatinib rather than developing chemicals that would non-
specifically scavenge ATP (Capdeville, Buchdunger, Zimmermann & Matter, 2002). 
From an epistemological perspective, the complexity of the place of ROS in cellular 
metabolism may be one of the reasons why it is difficult to answer the research 
question of the relevance of OS in many diseases. We could take a pragmatic 
approach, ex juvantibus; if an antioxidant will prove effective in disease X at the 
highest level of evidence required for drug approval, then we should conclude that OS 
is a cause of that disease. However, the molecules commonly used as antioxidants are 
not specific. For instance, all thiol-based antioxidants, such as GSH, are also reducing 
agents and will not only scavenge free radicals but will also reduce labile disulfides 
(Kim, Rhim, Choi & Kim, 2001; Laragione et al., 2003). Also the multiple sclerosis 
drug dimethyl fumarate, often considered to act by inducing antioxidant systems via 
Nrf2, has additional activities as it has therapeutic efficacy, regulating immunity, in a 
model of multiple sclerosis in Nrf2-deficient mice (Schulze-Topphoff et al., 2016). 
Therefore, a proof of efficacy would lead to the approval of the antioxidant tested for 
that specific indication but might not, alone, be a demonstration of the role of OS in 
that disease. 
Another possibility would be to better integrate and interpret existing knowledge. 
With hundreds of thousands of scientific publications on this topic, the demand for 
simplicity is strong. However, given the incredibly complex biology of ROS, we need 
to open up our small schemes and diagrams to integrate them with other metabolic 
pathways. There are of course ways of analysing or visualizing complex information, 
aggregating or integrating several experiments. For instance, meta-analysis can be 
used to combine the results of many clinical trials, often giving different results, to 
increase power by aggregating results. While this is typically used to analyse results 
of interventional trials, the approach has been used to combine studies on the 
association between biomarkers and disease (Flatow, Buckley & Miller, 2013). 
However, a meta-analysis can only respond to a simple question, such as the 
association of one variable with another (typically an outcome) but will not help 
integrating data from different experiments.  Other “big-data” approaches can give a 
better insight into common mechanisms of diseases. Barabasi has built diseasome 
network maps where diseases are associated to genes (Goh, Cusick, Valle, Childs, 
Vidal & Barabasi, 2007) or protein-protein interactions (Menche et al., 2015).  
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However, it is difficult, at this stage, to integrate experimental evidence obtained in 
too many different models and with very different methodologies. 
Open data: a proposal 
The real difficulty in using a big data approach is the well-known publication bias by 
which only so-called “positive results” are published. Anyone who has experience in 
the field knows that when we encounter two studies reporting that antioxidant X 
inhibits the production of mediator Z, it is possible that others have performed similar 
experiments and found no effect, or even the opposite effect but, because this was not 
the expected result, these “negative data” were not published. This is not specific for 
studies on OS and studies have shown that a very large proportion of scientific studies 
are not reproducible (Ioannidis, 2014). This does not necessarily imply scientific 
misconduct (such as not publishing negative data to please the funder).  Often the 
experimental design is so circumscribed (see 2.3. and the problem of external 
validity) that is only valid in that specific cell line, at that concentration and time 
point and researchers had to perform several experiments until they found the 
experimental conditions where “it works”. When a specific result is not reproducible 
in face of variations in the experimental conditions, it lacks robustness (Casadevall & 
Fang, 2010). Conversely, irreproducible results could be due to poorly circumscribed 
experimental set ups (Baetu, 2013): cell lines used at different passages or different 
density/confluence, in different culture media, time of incubation not properly 
followed to accommodate working hours, animals of different age and weight etc.  
Publishing negative results, those where the oxidant or antioxidant X “didn’t work”, 
would allow us using proper statistical analysis to compare different experiments, 
such as meta-analysis.  In clinical research, there is now a strong drive to make raw 
data of all clinical trials public. This philosophy should expand to basic research and 
repositories of open data. Making laboratory notebooks open and adopting well-
described standard protocols will eventually allow a quantification of the consistency 
of a given finding. One example is the application of the ARRIVE guidelines for 
reporting animal research (Kilkenny, Browne, Cuthill, Emerson & Altman, 2010) 
One could think, for instance, of having a network of scientists committed to open 
their lab notebooks and publish online all their results after a safe period, for instance 
one year. Funding agencies such as the National Institutes of Health (NIH) or the EU 
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will be key to these initiatives. An example is the NIH Data Sharing initiative 
(https://www.nlm.nih.gov/NIHbmic/nih_data_sharing_repositories.html), but one 
could think of specific initiatives on redox research aimed, for instance, at 
experiments using antioxidant or pro-oxidant interventions in vivo or in vitro, or 
measuring specific biomarkers. Funding agencies could also provide free open-access 
hosting, similar to the repositories used for microarray data for specific fields.  The 
availability of open data will eventually allow the set-up of networks similar to the 
Cochrane Collaboration. This will clearly need changing the mainstream culture 
around impact factor and the marked-oriented publication business. Only then would 
it be possible to think of extending the rigour of EBM to the formation of scientific 
theories.   
 
Conclusions 
Viewing the OS theory of disease from different theoretical perspectives developed in 
epistemological research, the theory comes out significantly weaker than many other 
pathogenic theories. This might explain why the translational shortcut of this theory, 
antioxidant therapy, has failed so often and has never shown enough evidence to be 
incorporated in guidelines, approved by regulatory agencies and recommended and 
reimbursed by health insurance systems basing their decisions on EBM criteria. 
We have seen that this is in part due to the technical difficulties of measuring ROS, an 
essential step to make a claim of a ROS-mediated disease, which is complicated by 
the large number of analytical techniques and analytes that have been used to make 
such claims. Trying to aggregate a plurality of diseases where different ROS are 
generated in different tissues by different sources may have aggravated the problem. 
The fact that antioxidants are not approved therapies for any disease (with the 
exception indicated above) does not of course rule out that OS may be a causal 
component of disease. Clinical evidence in favour of an association (but not a 
causative role) of OS with some diseases are strong. This was often showed in clinical 
trials, such as the EPIC trial reporting the benefit of consumption of fruits rich in 
vitamin C (Khaw et al., 2001). There may be technical reasons why this has not been 
convincing enough to recommend antioxidants as therapeutic agents. It may be that if 
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the same antioxidants had been given at a different dose, for a longer period of time or 
to a more selected cohort of the population, the results would have shown an efficacy 
at a sufficient level to allow their approval for that specific indication.  
In the present paper we tried to use a different, less explored, perspective to identify 
the weakness in the OS theory of disease that we may try to address in the future to 
improve the translational impact of studies in this field. Some of the issues 
(measuring ROS and their consequences with sensitivity and specificity) are 
inherently difficult to solve (Frijhoff et al., 2015). 
With the diversity of ROS generating systems and the wide variety of researchers 
(chemists, biochemists, pharmacologists, clinicians, etc.) studying ROS and their 
pathogenic role, if any, we suggest to prioritise the following: 
 (i) develop networks of international collaborations with shared results (open data, 
open lab notebooks, big data analysis, a Cochrane-style collaboration for preclinical 
studies), (ii) address the key question of how to demonstrate that OS is a causal 
component in disease X, (iii) sum up the level of evidence available rather than test 
another new antioxidant extracted from a different fruit, where a plethora of 
antioxidants from other sources have already been studied.  
Funding agencies need to encourage scientists to take the hardest route rather than go 
for the easy publication and the conventional wisdom of the dominant group. Finally, 
with the public’s growing expectations and understanding of science thanks to access 
to the information released by universities, companies and media, it is also the 
responsibility of scientists to adjudicate the claims of their scientific findings. This 
includes limitations in terms of component causes, level of evidence for making a 
causal claim, and the validity of the results outside their experimental system. Only 
critical, honest and out-of-the-box analysis of redox research will lead to the 
identification of redox pathways involved in pathologies and only then will innovative 
therapeutics be emerging. 
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